Advertisement
BBOT vs PRAX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBOT is a Hold and PRAX is a Buy.
BBOT's Indicator enters downward trend
The Aroon Indicator for BBOT entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 89 similar instances where the Aroon Indicator formed such a pattern. In 72 of the 89 cases the stock moved lower. This puts the odds of a downward move at 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBOT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BBOT's RSI Oscillator exited the oversold zone, 5 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBOT advanced for three days, in 45 of 71 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
BBOT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (3.498). P/E Ratio (-0.897) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. BBOT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBOT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for PRAX turns positive, indicating new upward trend
PRAX saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned positive. In 89 of the 96 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PRAX just turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 41 of 43 cases over the following month. The odds of a continued upward trend are 90%.
PRAX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +21.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 257 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for PRAX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
PRAX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PRAX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.780) is normal, around the industry mean (3.498). P/E Ratio (-21.421) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
PRAX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 85 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 38 | |
P/E GROWTH RATING 1..100 | 33 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BBOT | PRAX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 79% |
| Momentum ODDS (%) | N/A | 2 days ago 90% |
| MACD ODDS (%) | N/A | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 51% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 53% | 2 days ago 89% |
| Advances ODDS (%) | 15 days ago 63% | 2 days ago 85% |
| Declines ODDS (%) | 6 days ago 75% | 10 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 58% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BBOT’s FA Score shows that 1 FA rating(s) are green while PRAX’s FA Score has 2 green FA rating(s).
- BBOT’s FA Score: 1 green, 4 red.
- PRAX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BBOT’s TA Score shows that 4 TA indicator(s) are bullish while PRAX’s TA Score has 4 bullish TA indicator(s).
- BBOT’s TA Score: 4 bullish, 2 bearish.
- PRAX’s TA Score: 4 bullish, 6 bearish.
Price Growth
BBOT (@Biotechnology) experienced а -5.17% price change this week, while PRAX (@Biotechnology) price change was +20.35% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
BBOT is expected to report earnings on Nov 11, 2026.
PRAX is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BBOT and
Correlation & Price change
A.I.dvisor indicates that over the last year, BBOT has been loosely correlated with PRAX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BBOT jumps, then PRAX could also see price increases.
| Ticker / NAME | Correlation To BBOT | 1D Price Change % | ||
|---|---|---|---|---|
| BBOT | 100% | -4.35% | ||
| PRAX - BBOT | 39% Loosely correlated | +1.39% | ||
| MLTX - BBOT | 38% Loosely correlated | -0.48% | ||
| LXEO - BBOT | 38% Loosely correlated | -2.55% | ||
| COYA - BBOT | 37% Loosely correlated | -5.11% | ||
| MIST - BBOT | 35% Loosely correlated | -10.27% | ||
More | ||||
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with FULC. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then FULC could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | +1.39% | ||
| FULC - PRAX | 45% Loosely correlated | N/A | ||
| IMVT - PRAX | 44% Loosely correlated | +1.59% | ||
| LXEO - PRAX | 43% Loosely correlated | -2.55% | ||
| CGEM - PRAX | 42% Loosely correlated | -4.26% | ||
| CELC - PRAX | 42% Loosely correlated | -4.72% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ROKT | 102.70 | 0.82 | +0.80% |
| State Street SPDR S&P Kensho Final Frontiers ETF (ROKT) | |||
| TEQI | 53.76 | 0.11 | +0.21% |
| T. Rowe Price Equity Income ETF (TEQI) | |||
| BUYZ | 35.90 | N/A | N/A |
| Franklin Disruptive Commerce ETF (BUYZ) | |||
| SLDR | 49.42 | -0.08 | -0.16% |
| Global X Short-Term Treasury Ladder ETF (SLDR) | |||
| QGRW | 63.89 | -0.50 | -0.78% |
| WisdomTree U.S. Quality Growth Fund (QGRW) | |||